A VersaTile-driven platform for rapid hit-to-lead development of engineered lysins.

ABSTRACT: Health care authorities are calling for new antibacterial therapies to cope with the global emergence of antibiotic-resistant bacteria. Bacteriophage-encoded lysins are a unique class of antibacterials with promising (pre)clinical progress. Custom engineering of lysins allows for the creation of variants against potentially any bacterial pathogen. We here present a high-throughput hit-to-lead development platform for engineered lysins. The platform is driven by VersaTile, a new DNA assembly method for the rapid construction of combinatorial libraries of engineered lysins. We constructed approximately 10,000 lysin variants. Using an iterative screening procedure, we identified a lead variant with high antibacterial activity against Acinetobacter baumannii in human serum and an ex viv

SUBMITTER: Gerstmans H 

PROVIDER: S-EPMC7269649 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature